GENERAL30 Sept 2026
Molbio gains 9% as Jefferies assigns 'Buy' tag on innovation-led model
Molbio Diagnostics shares rose 9% after Jefferies gave the stock a 'Buy' rating and called it a high-conviction pick. Jefferies set a target price of ₹1,600, which points to a 27% upside from the last closing price of ₹1,255.60. This affects existing and prospective investors. Treat it as one broker's view, not a guarantee, and check your own goals before acting.
Key Statutory Highlights
- Jefferies has rated Molbio Diagnostics a 'Buy' and described it as a high-conviction pick.
- The brokerage set a target price of ₹1,600 on the Molbio counter.
- That target works out to a 27% upside from Molbio's last closing price of ₹1,255.60, and the shares gained 9%.
Actionable Advice for Taxpayers / Founders:If you hold or are considering Molbio shares, remember this is one broker's opinion and not a promise of returns. Review it against your own goals, time frame and risk comfort, and consider speaking to a registered investment adviser before you buy or sell.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: